Brand Intelligence Graph
Company Overview
About Ro Pharmacy
Ro is a New York-based digital health platform — backed with $876 million raised from General Catalyst, SignalFire, L Catterton, and others at a peak $7 billion valuation — providing telemedicine consultations, prescription management, and pharmacy-grade medication delivery for men's health (erectile dysfunction, hair loss under the Roman brand), women's health (fertility, menopause under the Rory brand), primary care (Ro Primary Care), and weight management (body program with GLP-1 medications). Founded in 2017 by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, Ro generated approximately $350 million in revenue in 2024, serving over 2 million patients who have completed consultations through its platforms.
Business Model & Competitive Advantage
Ro's vertically integrated model is the operational differentiator: rather than contracting with third-party pharmacies (as most telehealth platforms do), Ro owns and operates its own pharmacy infrastructure (Ro Pharmacy, a licensed dispensary in multiple states). This vertical integration enables the $99/month ED medication subscription, the same-day compounded semaglutide dispensing for weight management, and the generic medication pricing that drives patient economics for chronic condition management. The asynchronous consultation model (patients complete a health questionnaire, a licensed physician reviews it and issues a prescription) enables 24/7 prescription access without appointment scheduling.
Competitive Landscape 2025–2026
In 2025, Ro competes in the direct-to-consumer telehealth and prescription delivery market with Hims & Hers (NYSE: HIMS, the primary direct competitor for men's and women's health), Noom (weight management), and Amazon Clinic (AMZN, telehealth expansion) for digital health patient acquisition. Hims & Hers has grown aggressively in GLP-1 compounded semaglutide (weight management) and gained significant scale, while Ro's Roman and Rory brands retain strong brand equity in their core men's and women's health audiences. The compounded GLP-1 market is in regulatory flux — FDA policies on compounding pharmacies and Novo Nordisk's Ozempic drug shortage status affect both Ro's and Hims's GLP-1 businesses. The 2025 strategy focuses on primary care membership growth, GLP-1 program expansion, and building the chronic condition management platform (diabetes, hypertension) beyond the branded health conditions.
Recent Activity
View all →Foreign Filing filed 2026-05-07
Foreign Filing filed 2026-05-07
Foreign Filing filed 2026-04-16
Foreign Filing filed 2026-04-02
Annual Report (foreign) filed 2026-04-02
Foreign Filing filed 2026-03-27
Foreign Filing filed 2026-03-24
Key Differentiators
Emerging Innovator
Ro Pharmacy is an emerging player bringing innovative solutions to the Healthcare market.
Growth Stage
Ro Pharmacy has achieved $350M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Compare Ro Pharmacy with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Ro Pharmacy? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Ro Pharmacy Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Ro Pharmacy vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →